NCT07143929

To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL

An Open-label, Dose-escalation Early-phase Clinical Study of CD7-targeted CAR-T Cells for the Treatment of Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 18 (estimated)
• Sponsor: Peking University People's Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To observe the efficacy and safety of CD7-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed PTCL.

Detailed description

In this study, anti CD7 CAR-T cell therapy will be explored for patients with relapsed/refractory PTCL. In this study, the 3+3 dose climbing mode will be used to explore the safety and efficacy of CAR-T cells in r/r PTCL therapy at different doses. The RP2D dose will be determined after the relevant data is summarized。

Conditions

• CD7 Positive R/R PTCL

Interventions

Type	Name	Description
DRUG	CAR-T	autologous CD7-targeted CAR-T cells, single injection

Timeline

• Start date: 2025-08-18
• Primary completion: 2026-07-31
• Completion: 2027-12-31
• First posted: 2025-08-27
• Last updated: 2025-08-27

Locations

1 site across 1 country: China